nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—GART—myocardium—dilated cardiomyopathy	0.0392	0.152	CbGeAlD
Pemetrexed—GART—heart—dilated cardiomyopathy	0.0273	0.106	CbGeAlD
Pemetrexed—GART—cardiac atrium—dilated cardiomyopathy	0.0234	0.0906	CbGeAlD
Pemetrexed—DHFR—cardiac ventricle—dilated cardiomyopathy	0.019	0.0735	CbGeAlD
Pemetrexed—ATIC—heart—dilated cardiomyopathy	0.0186	0.0719	CbGeAlD
Pemetrexed—DHFR—myocardium—dilated cardiomyopathy	0.0179	0.0692	CbGeAlD
Pemetrexed—SLC29A1—cardiac ventricle—dilated cardiomyopathy	0.0172	0.0666	CbGeAlD
Pemetrexed—SLC29A1—myocardium—dilated cardiomyopathy	0.0162	0.0626	CbGeAlD
Pemetrexed—DCK—myocardium—dilated cardiomyopathy	0.0154	0.0598	CbGeAlD
Pemetrexed—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.0143	0.0254	CcSEcCtD
Pemetrexed—GART—Purine metabolism—GPX1—dilated cardiomyopathy	0.0143	0.0809	CbGpPWpGaD
Pemetrexed—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.0139	0.0247	CcSEcCtD
Pemetrexed—Thrombosis—Furosemide—dilated cardiomyopathy	0.0136	0.0241	CcSEcCtD
Pemetrexed—DHFR—heart—dilated cardiomyopathy	0.0125	0.0483	CbGeAlD
Pemetrexed—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.0116	0.0205	CcSEcCtD
Pemetrexed—SLC29A1—heart—dilated cardiomyopathy	0.0113	0.0437	CbGeAlD
Pemetrexed—DCK—heart—dilated cardiomyopathy	0.0108	0.0418	CbGeAlD
Pemetrexed—DHFR—cardiac atrium—dilated cardiomyopathy	0.0107	0.0413	CbGeAlD
Pemetrexed—Heartburn—Lisinopril—dilated cardiomyopathy	0.0105	0.0186	CcSEcCtD
Pemetrexed—ATIC—Purine metabolism—GPX1—dilated cardiomyopathy	0.00988	0.0561	CbGpPWpGaD
Pemetrexed—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00984	0.0174	CcSEcCtD
Pemetrexed—Renal failure—Spironolactone—dilated cardiomyopathy	0.00975	0.0172	CcSEcCtD
Pemetrexed—SLC29A1—cardiac atrium—dilated cardiomyopathy	0.00965	0.0374	CbGeAlD
Pemetrexed—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00926	0.0164	CcSEcCtD
Pemetrexed—DCK—cardiac atrium—dilated cardiomyopathy	0.00922	0.0357	CbGeAlD
Pemetrexed—GART—Folate Metabolism—SOD2—dilated cardiomyopathy	0.00858	0.0487	CbGpPWpGaD
Pemetrexed—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00842	0.0149	CcSEcCtD
Pemetrexed—GART—Folate Metabolism—GPX1—dilated cardiomyopathy	0.00819	0.0465	CbGpPWpGaD
Pemetrexed—Alopecia—Spironolactone—dilated cardiomyopathy	0.00787	0.0139	CcSEcCtD
Pemetrexed—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.00776	0.0137	CcSEcCtD
Pemetrexed—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00761	0.0134	CcSEcCtD
Pemetrexed—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00724	0.0128	CcSEcCtD
Pemetrexed—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00724	0.0128	CcSEcCtD
Pemetrexed—GART—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00716	0.0407	CbGpPWpGaD
Pemetrexed—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00694	0.0123	CcSEcCtD
Pemetrexed—Neuropathy—Lisinopril—dilated cardiomyopathy	0.0068	0.012	CcSEcCtD
Pemetrexed—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00656	0.0116	CcSEcCtD
Pemetrexed—Dehydration—Furosemide—dilated cardiomyopathy	0.00651	0.0115	CcSEcCtD
Pemetrexed—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00633	0.0112	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00631	0.0112	CcSEcCtD
Pemetrexed—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.0062	0.011	CcSEcCtD
Pemetrexed—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00594	0.0105	CcSEcCtD
Pemetrexed—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00582	0.0103	CcSEcCtD
Pemetrexed—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00569	0.0101	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00546	0.00966	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00536	0.00948	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00535	0.00946	CcSEcCtD
Pemetrexed—Renal failure—Furosemide—dilated cardiomyopathy	0.00531	0.00938	CcSEcCtD
Pemetrexed—DCK—Purine metabolism—GPX1—dilated cardiomyopathy	0.00514	0.0292	CbGpPWpGaD
Pemetrexed—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00511	0.00903	CcSEcCtD
Pemetrexed—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00504	0.00891	CcSEcCtD
Pemetrexed—Urticaria—Spironolactone—dilated cardiomyopathy	0.00503	0.00889	CcSEcCtD
Pemetrexed—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.005	0.00884	CcSEcCtD
Pemetrexed—ATIC—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00497	0.0282	CbGpPWpGaD
Pemetrexed—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00492	0.0087	CcSEcCtD
Pemetrexed—Dehydration—Lisinopril—dilated cardiomyopathy	0.00489	0.00864	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00485	0.0275	CbGpPWpGaD
Pemetrexed—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00479	0.00846	CcSEcCtD
Pemetrexed—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00475	0.0084	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00473	0.00837	CcSEcCtD
Pemetrexed—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00466	0.00824	CcSEcCtD
Pemetrexed—SLC46A1—Folate Metabolism—SOD2—dilated cardiomyopathy	0.00464	0.0263	CbGpPWpGaD
Pemetrexed—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00458	0.0081	CcSEcCtD
Pemetrexed—Eye disorder—Furosemide—dilated cardiomyopathy	0.00453	0.00801	CcSEcCtD
Pemetrexed—Pruritus—Spironolactone—dilated cardiomyopathy	0.00448	0.00792	CcSEcCtD
Pemetrexed—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00445	0.00787	CcSEcCtD
Pemetrexed—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00443	0.00782	CcSEcCtD
Pemetrexed—SLC46A1—Folate Metabolism—GPX1—dilated cardiomyopathy	0.00442	0.0251	CbGpPWpGaD
Pemetrexed—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00433	0.00765	CcSEcCtD
Pemetrexed—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00433	0.00765	CcSEcCtD
Pemetrexed—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00431	0.00763	CcSEcCtD
Pemetrexed—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00425	0.00751	CcSEcCtD
Pemetrexed—Erythema—Furosemide—dilated cardiomyopathy	0.00422	0.00746	CcSEcCtD
Pemetrexed—Malnutrition—Furosemide—dilated cardiomyopathy	0.00422	0.00746	CcSEcCtD
Pemetrexed—Dizziness—Spironolactone—dilated cardiomyopathy	0.00418	0.0074	CcSEcCtD
Pemetrexed—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00413	0.0073	CcSEcCtD
Pemetrexed—Vomiting—Spironolactone—dilated cardiomyopathy	0.00402	0.00711	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00402	0.0071	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00399	0.00706	CcSEcCtD
Pemetrexed—Rash—Spironolactone—dilated cardiomyopathy	0.00399	0.00705	CcSEcCtD
Pemetrexed—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00399	0.00705	CcSEcCtD
Pemetrexed—Renal failure—Lisinopril—dilated cardiomyopathy	0.00398	0.00704	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00397	0.00702	CcSEcCtD
Pemetrexed—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00397	0.00702	CcSEcCtD
Pemetrexed—Anaemia—Furosemide—dilated cardiomyopathy	0.0039	0.00689	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00383	0.00677	CcSEcCtD
Pemetrexed—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00378	0.00668	CcSEcCtD
Pemetrexed—Leukopenia—Furosemide—dilated cardiomyopathy	0.00378	0.00668	CcSEcCtD
Pemetrexed—Nausea—Spironolactone—dilated cardiomyopathy	0.00376	0.00665	CcSEcCtD
Pemetrexed—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00364	0.00643	CcSEcCtD
Pemetrexed—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00361	0.00638	CcSEcCtD
Pemetrexed—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00359	0.00635	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00357	0.00631	CcSEcCtD
Pemetrexed—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00356	0.0063	CcSEcCtD
Pemetrexed—SLC29A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00351	0.0199	CbGpPWpGaD
Pemetrexed—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00344	0.00609	CcSEcCtD
Pemetrexed—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00344	0.00608	CcSEcCtD
Pemetrexed—Shock—Furosemide—dilated cardiomyopathy	0.00339	0.00599	CcSEcCtD
Pemetrexed—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00338	0.00597	CcSEcCtD
Pemetrexed—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00337	0.00596	CcSEcCtD
Pemetrexed—Skin disorder—Furosemide—dilated cardiomyopathy	0.00334	0.00591	CcSEcCtD
Pemetrexed—Anorexia—Furosemide—dilated cardiomyopathy	0.00328	0.0058	CcSEcCtD
Pemetrexed—GART—Folate Metabolism—TNF—dilated cardiomyopathy	0.00325	0.0185	CbGpPWpGaD
Pemetrexed—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00325	0.00574	CcSEcCtD
Pemetrexed—Alopecia—Lisinopril—dilated cardiomyopathy	0.00321	0.00568	CcSEcCtD
Pemetrexed—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00317	0.0056	CcSEcCtD
Pemetrexed—Erythema—Lisinopril—dilated cardiomyopathy	0.00317	0.0056	CcSEcCtD
Pemetrexed—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.0031	0.00548	CcSEcCtD
Pemetrexed—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00299	0.00529	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00297	0.00525	CcSEcCtD
Pemetrexed—Fatigue—Furosemide—dilated cardiomyopathy	0.00297	0.00525	CcSEcCtD
Pemetrexed—Pain—Furosemide—dilated cardiomyopathy	0.00294	0.0052	CcSEcCtD
Pemetrexed—Constipation—Furosemide—dilated cardiomyopathy	0.00294	0.0052	CcSEcCtD
Pemetrexed—Anaemia—Lisinopril—dilated cardiomyopathy	0.00293	0.00517	CcSEcCtD
Pemetrexed—Syncope—Lisinopril—dilated cardiomyopathy	0.00284	0.00502	CcSEcCtD
Pemetrexed—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00283	0.00501	CcSEcCtD
Pemetrexed—GART—Metabolism—ANKRD1—dilated cardiomyopathy	0.00282	0.016	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00282	0.00498	CcSEcCtD
Pemetrexed—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00278	0.00492	CcSEcCtD
Pemetrexed—Urticaria—Furosemide—dilated cardiomyopathy	0.00274	0.00484	CcSEcCtD
Pemetrexed—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00272	0.00481	CcSEcCtD
Pemetrexed—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00272	0.00481	CcSEcCtD
Pemetrexed—Chest pain—Lisinopril—dilated cardiomyopathy	0.00269	0.00476	CcSEcCtD
Pemetrexed—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00269	0.00476	CcSEcCtD
Pemetrexed—Myalgia—Lisinopril—dilated cardiomyopathy	0.00269	0.00476	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00268	0.00473	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00265	0.0151	CbGpPWpGaD
Pemetrexed—GART—Metabolism—TAZ—dilated cardiomyopathy	0.00265	0.015	CbGpPWpGaD
Pemetrexed—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00258	0.00457	CcSEcCtD
Pemetrexed—Oedema—Lisinopril—dilated cardiomyopathy	0.00258	0.00457	CcSEcCtD
Pemetrexed—DCK—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00258	0.0147	CbGpPWpGaD
Pemetrexed—Infection—Lisinopril—dilated cardiomyopathy	0.00257	0.00454	CcSEcCtD
Pemetrexed—Shock—Lisinopril—dilated cardiomyopathy	0.00254	0.00449	CcSEcCtD
Pemetrexed—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00254	0.00448	CcSEcCtD
Pemetrexed—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00253	0.00447	CcSEcCtD
Pemetrexed—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00251	0.00444	CcSEcCtD
Pemetrexed—DHFR—Folate Metabolism—SOD2—dilated cardiomyopathy	0.00249	0.0141	CbGpPWpGaD
Pemetrexed—Asthenia—Furosemide—dilated cardiomyopathy	0.00247	0.00437	CcSEcCtD
Pemetrexed—Anorexia—Lisinopril—dilated cardiomyopathy	0.00246	0.00435	CcSEcCtD
Pemetrexed—Pruritus—Furosemide—dilated cardiomyopathy	0.00244	0.00431	CcSEcCtD
Pemetrexed—GART—Metabolism—SDHA—dilated cardiomyopathy	0.0024	0.0136	CbGpPWpGaD
Pemetrexed—DHFR—Folate Metabolism—GPX1—dilated cardiomyopathy	0.00237	0.0135	CbGpPWpGaD
Pemetrexed—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00236	0.00416	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00235	0.00416	CcSEcCtD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00231	0.0131	CbGpPWpGaD
Pemetrexed—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.0023	0.00407	CcSEcCtD
Pemetrexed—Dizziness—Furosemide—dilated cardiomyopathy	0.00228	0.00402	CcSEcCtD
Pemetrexed—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00227	0.00402	CcSEcCtD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00225	0.0128	CbGpPWpGaD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00225	0.0128	CbGpPWpGaD
Pemetrexed—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00225	0.00397	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00223	0.00394	CcSEcCtD
Pemetrexed—Fatigue—Lisinopril—dilated cardiomyopathy	0.00223	0.00394	CcSEcCtD
Pemetrexed—Constipation—Lisinopril—dilated cardiomyopathy	0.00221	0.00391	CcSEcCtD
Pemetrexed—Pain—Lisinopril—dilated cardiomyopathy	0.00221	0.00391	CcSEcCtD
Pemetrexed—Vomiting—Furosemide—dilated cardiomyopathy	0.00219	0.00387	CcSEcCtD
Pemetrexed—Rash—Furosemide—dilated cardiomyopathy	0.00217	0.00384	CcSEcCtD
Pemetrexed—Dermatitis—Furosemide—dilated cardiomyopathy	0.00217	0.00383	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00211	0.00373	CcSEcCtD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00209	0.0119	CbGpPWpGaD
Pemetrexed—Urticaria—Lisinopril—dilated cardiomyopathy	0.00205	0.00363	CcSEcCtD
Pemetrexed—Nausea—Furosemide—dilated cardiomyopathy	0.00205	0.00362	CcSEcCtD
Pemetrexed—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00204	0.00361	CcSEcCtD
Pemetrexed—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00204	0.00361	CcSEcCtD
Pemetrexed—ATIC—Metabolism—ANKRD1—dilated cardiomyopathy	0.00195	0.0111	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.0019	0.00336	CcSEcCtD
Pemetrexed—Asthenia—Lisinopril—dilated cardiomyopathy	0.00185	0.00328	CcSEcCtD
Pemetrexed—ATIC—Metabolism—TAZ—dilated cardiomyopathy	0.00184	0.0104	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00184	0.0104	CbGpPWpGaD
Pemetrexed—Pruritus—Lisinopril—dilated cardiomyopathy	0.00183	0.00323	CcSEcCtD
Pemetrexed—TYMS—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00181	0.0103	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00181	0.0102	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00179	0.0101	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00179	0.0101	CbGpPWpGaD
Pemetrexed—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00177	0.00312	CcSEcCtD
Pemetrexed—SLC46A1—Folate Metabolism—TNF—dilated cardiomyopathy	0.00176	0.00998	CbGpPWpGaD
Pemetrexed—Dizziness—Lisinopril—dilated cardiomyopathy	0.00171	0.00302	CcSEcCtD
Pemetrexed—ATIC—Metabolism—SDHA—dilated cardiomyopathy	0.00166	0.00943	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00166	0.00942	CbGpPWpGaD
Pemetrexed—Vomiting—Lisinopril—dilated cardiomyopathy	0.00164	0.0029	CcSEcCtD
Pemetrexed—Rash—Lisinopril—dilated cardiomyopathy	0.00163	0.00288	CcSEcCtD
Pemetrexed—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00163	0.00288	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—TUBB—dilated cardiomyopathy	0.00161	0.00916	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00161	0.00914	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00158	0.00894	CbGpPWpGaD
Pemetrexed—Nausea—Lisinopril—dilated cardiomyopathy	0.00153	0.00271	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.00152	0.00864	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00151	0.00859	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.00144	0.00817	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—EMD—dilated cardiomyopathy	0.00144	0.00817	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—TAZ—dilated cardiomyopathy	0.00143	0.00812	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TUBB—dilated cardiomyopathy	0.00141	0.008	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.0014	0.00797	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—ALMS1—dilated cardiomyopathy	0.00135	0.00768	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00132	0.00749	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—SDHA—dilated cardiomyopathy	0.00129	0.00734	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—EMD—dilated cardiomyopathy	0.00126	0.00713	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—ALMS1—dilated cardiomyopathy	0.00118	0.0067	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.00116	0.00657	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ANKRD1—dilated cardiomyopathy	0.00102	0.00576	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.00101	0.00573	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000957	0.00543	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—TAZ—dilated cardiomyopathy	0.000955	0.00542	CbGpPWpGaD
Pemetrexed—DHFR—Folate Metabolism—TNF—dilated cardiomyopathy	0.000942	0.00535	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—SDHA—dilated cardiomyopathy	0.000863	0.0049	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000858	0.00487	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TMPO—dilated cardiomyopathy	0.000856	0.00486	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000835	0.00474	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000828	0.0047	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ANKRD1—dilated cardiomyopathy	0.000816	0.00463	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000812	0.00461	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000795	0.00451	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NPPA—dilated cardiomyopathy	0.000791	0.00449	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000786	0.00446	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TAZ—dilated cardiomyopathy	0.000767	0.00435	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PSEN2—dilated cardiomyopathy	0.000766	0.00435	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TMPO—dilated cardiomyopathy	0.000747	0.00424	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ANKRD1—dilated cardiomyopathy	0.000712	0.00404	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—LMNA—dilated cardiomyopathy	0.000703	0.00399	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SDHA—dilated cardiomyopathy	0.000694	0.00394	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000686	0.00389	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—TAZ—dilated cardiomyopathy	0.000669	0.0038	CbGpPWpGaD
Pemetrexed—GART—Metabolism—GPX1—dilated cardiomyopathy	0.000651	0.00369	CbGpPWpGaD
Pemetrexed—GART—Metabolism—CD36—dilated cardiomyopathy	0.000634	0.0036	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—LMNA—dilated cardiomyopathy	0.000613	0.00348	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SDHA—dilated cardiomyopathy	0.000605	0.00344	CbGpPWpGaD
Pemetrexed—GART—Metabolism—AGT—dilated cardiomyopathy	0.000571	0.00324	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000538	0.00305	CbGpPWpGaD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000457	0.00259	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GPX1—dilated cardiomyopathy	0.000451	0.00256	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CD36—dilated cardiomyopathy	0.000439	0.00249	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NPPA—dilated cardiomyopathy	0.000424	0.00241	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PSEN2—dilated cardiomyopathy	0.000411	0.00233	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—AGT—dilated cardiomyopathy	0.000396	0.00225	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—RAC1—dilated cardiomyopathy	0.000385	0.00219	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000369	0.00209	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000362	0.00206	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GPX1—dilated cardiomyopathy	0.000351	0.00199	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000351	0.00199	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CD36—dilated cardiomyopathy	0.000342	0.00194	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—AGT—dilated cardiomyopathy	0.000308	0.00175	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—RAF1—dilated cardiomyopathy	0.000255	0.00145	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GPX1—dilated cardiomyopathy	0.000235	0.00133	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CD36—dilated cardiomyopathy	0.000228	0.0013	CbGpPWpGaD
Pemetrexed—DHFR—Disease—RAC1—dilated cardiomyopathy	0.000207	0.00117	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—AGT—dilated cardiomyopathy	0.000206	0.00117	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GPX1—dilated cardiomyopathy	0.000188	0.00107	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CD36—dilated cardiomyopathy	0.000184	0.00104	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGFR—dilated cardiomyopathy	0.000175	0.000994	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—AGT—dilated cardiomyopathy	0.000165	0.000938	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GPX1—dilated cardiomyopathy	0.000164	0.000933	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CD36—dilated cardiomyopathy	0.00016	0.000909	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—AGT—dilated cardiomyopathy	0.000144	0.000818	CbGpPWpGaD
Pemetrexed—DHFR—Disease—RAF1—dilated cardiomyopathy	0.000137	0.000777	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGFR—dilated cardiomyopathy	9.39e-05	0.000533	CbGpPWpGaD
